Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2003-12-29
2009-10-06
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S144100
Reexamination Certificate
active
07597887
ABSTRACT:
The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-γ by lymphocytes or other immune cells in a mammal. Inhibition of IFN-γ is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.
REFERENCES:
patent: 5622861 (1997-04-01), Kaplan et al.
patent: 6084083 (2000-07-01), Levinson
patent: 6664385 (2003-12-01), Sanicola-Nadel et al.
patent: 2003/0124114 (2003-07-01), McIntire et al.
patent: 2003/0215831 (2003-11-01), Sanicola- Nadel et al.
patent: 2004/0005322 (2004-01-01), Kuchroo et al.
patent: 2004/0180038 (2004-09-01), Hancock et al.
patent: 2005/0014687 (2005-01-01), Anderson et al.
patent: 2005/0095593 (2005-05-01), McIntire et al.
patent: 2005/0112117 (2005-05-01), Bailly et al.
patent: 2005/0276756 (2005-12-01), Hoo et al.
patent: 1062949 (2000-12-01), None
patent: WO 96/04376 (1996-02-01), None
patent: WO 97/44459 (1997-11-01), None
patent: WO 97/44460 (1997-11-01), None
patent: WO 98/20110 (1998-05-01), None
patent: WO 01/98481 (2001-12-01), None
patent: WO 02/098920 (2002-12-01), None
patent: WO 03/025138 (2003-03-01), None
patent: WO 03/042661 (2003-05-01), None
patent: WO 03/080856 (2003-10-01), None
patent: WO 2004/005544 (2004-01-01), None
patent: WO 2004/084823 (2004-10-01), None
patent: WO 2005/001092 (2005-01-01), None
Xiao et al. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med. Jul. 9, 2007;204(7):1691-702.
Umetsu et al. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol. May 2005;6(5):447-54.
Hoo et al. Vaccination with cell immunoglobulin mucin-1 antibodies and inactivated influenza enhances vaccine-specific lymphocyte proliferation, interferon-gamma production and cross-strain reactivity. Clin Exp Immunol. Jul. 2006;145(1):123-9.
Stites et al. Basic and Clinical Immunlogy, 8th edition, pp. 30-31,208-209, 246-247, 1994.
Piccotti Jr et al. Interleukin-12 (IL-12)-driven alloimmune. Transplantation. Jun. 15, 1999;67(11):1453-60.
Campo Ca et al. Zinc inhibits the mixed lymphocyte culture. Biol Trace Elem Res. Jan. 2001;79(1):15-22.
Reinsmoen et al. Evaluation of the Cellular Immune Response in Transplantation. In Manual of Clinical Laboratory Immunology, 6th Edition, by Rose, N. R., pp. 1164-1175, 1994.
Bailly, V., et al., “Shedding of Kidney Injury Molecule-1, a Putative Adhesion Protein Involved in Renal Regeneration,” Journal of Biological Chemistry, (2002) 277(42):39739-39748.
Berg et al., “L-selectin-mediated Lymphocyte Rolling on MadCAM-1,” Nature (1993) 366:695-698.
Berlin et al., “alpha-4-beta-7 Integrin Mediates Lymphocyte Binding to the Mucosal Vascular Address in MAdCAM-1,” Cell (1993) 74:185-195.
Bonventre and Colvin, “Adhesion Molecules in Renal Disease,” Current Opinion in Nephrology and Hypertension (1996) 5:254-261.
Briskin et al., “MAdCAM-1 has Homology to Immunoglobulin and Mucin-like Adhesion Receptors and to IgA1,” Nature (1993) 363:461-464.
Database No. AC005603,Homo sapienssubtelomeric cosmid 11b-1,Sep. 3, 1998.
Database Accession No. AC026777,Homo sapienschromosome 5 clone CTC-332D4, complete sequence, retrieved from EMBL, Mar. 27, 2000.
Database Accession No. AQ277590, “CITBI-E1-2517G14.TFCITBI-E1Homo sapiensgenomic clone 2517G14, genomic survey sequence,” retrieved from EMBL, Nov. 23, 1998.
Database Accession No. AL022721, “Human DNA Sequence from clone 109F14 on chromosome 6p21.2-21.3”, retrieved from EMBL, Apr. 27, 1998.
Dudley et al., “A Requirement for Bone Morphogenetic Protein-7 During Development of the Mammalian Kidney and Eye,” Genes & Development (1995) 9:2795-2807.
Encinas et al., “Anti-T-Cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma.”, J. of Allergy and Clinical Immunol. (2005), 116(6):1343-1349, (XP002367404).
Faure et al., “Differentially Expressed Genes in Ischemic Acute Renal Failure”, Mol. Biol. Of the Cell, Bethesda, MD, 1998, 9:473A (XP-000953127).
Fagotto and Gumbiner, “Cell Contact-Dependent Signaling,” Developmental Biology (1996) 180:445-454.
Feigelstock et al., “The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor,” J. Virol. (1998) 72:6621-6628.
Ferrara et al., “Monoclonal Antibody And Receptor Antagonist Therapy for GVHD.”, Cancer Treatment and Research, (1999), 101:331-368.
Greve et al., “The Major Human Rhinovirus Receptor Is ICAM-1,” Cell (1989) 56:839-847.
Gorczynski et al., “A CD200FC Immunoadhesin Prolongs Rat Islet Xenograft Survival in Mice.”, Transplantation, Williams and Wilkins, Baltimore, MD, US., (2002), 73(12):1948-1953.
Han, W. et al., “Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury,” Kidney International, (2001, 62(1):237-244.
Hubank and Schatz. “Identifying Differences in mRNA Expression by Representational Difference Analysis of cDNA,” Nucleic Acids Research (1994) 22:5640-5648.
Ichimura et al., “Kidney Injury Molecule-1 (KIM-1), a Putative Epithelial Cell Adhesion Molecule . . . ”. J. Biol. Chem. 273(7):4135-4142, 1998.
Kaplan et al. “Identification of a Surface Glycoprotein on African Green Monkey Kidney Cells as a Receptor for Hepatitis A Virus,” EMBO (1996) 15:4282-96.
Klinken et al, “Mucin Gene Structure and Expression: Protection vs. Adhesion,” Am J. Physiol. (1995) 269:G613-G627.
Kuchroo, et al. “TheTimGene Family: Emerging Roles in Immunity and Disease,” Nat. Rev. Immunol. (2003) 3:454-62.
Kumanogoh et al. “Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2” Nature (2002) 419:629-33.
Lin G. et al., “Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissues” Eur. J. Immunol. (1995) 25:1508-1516.
Luo et al., “BMP-7 is an Inducer of Nephrogenesis and is also Required for Eye Development and Skeletal Patterning,” Genes & Development (1995) 9:2808-2820.
McIntire et al. “Identification ofTapr(An Airway Hyperreactivity Regulator Locus) and the LinkedTimGene Family,” Nat. Immunol. (2001):2:1109-16.
Monney et al., “Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease,” Nature (2002) 415:536-41.
Muller et al., “Integrin alpha8-beta1 is Critically Important for Epithelial-Mesenchymal Interactions During Kidney Morphogenesis” Cell (1997) 88:603-613.
Owens et al., “The genetic engineering of monoclonal antibodies,” J. Immunol. Methods. (1994) 168:149-165.
Padanilam et al., Molecular mechanisms of cell death and regeneration in acute ischemic renal injury, Current Opinion in Nephrology and Hypertension, Rapid Science, London GB 1999, 81(1):15-19 (XP-000953223).
Prinz et al., “Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412.”, J. of the American Academy of Dermatology, (1996), 34:244-52.
Rieger et al., Glossary of Genetics. 5th Edition, Springer-Verlag, NY, (1991) 16-17.
Rosenberg et al., “Differential gene expression in the recovery from the ischemic renal injury”, Kidney International 39:1156-1161, 1991 (XP-000953186).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Nat. Acad. Sci., USA, (1982) 79:1979-1983.
Sastry and Horwitz, “Adhesion-Growth Factor Interactions During Differentiation: An Integrated Biological Response,
Biogen Idec MA Inc.
Fish & Richardson P.C.
Haddad Maher M
LandOfFree
KIM-1 antagonists and use to modulate immune system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with KIM-1 antagonists and use to modulate immune system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and KIM-1 antagonists and use to modulate immune system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4123034